title: Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
abstract: OBJECTIVE
  To identify characteristics of the cell-mediated immune (CMI) response to human papillomavirus-16 (HPV) E7 viral peptide pools to help the formulation of therapeutic vaccines.
  
  
  METHODS
  Prospective study. Population. Korean women.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  From December 2008 to August 2010, 33 HPV-16-positive patients, seven patients exhibiting a high-risk HPV infection other than HPV-16 with grade 2/3 cervical intraepithelial neoplasm (CIN2/3), and nine healthy control donors were enrolled.
  
  
  METHODS
  CMI response to synthetic HPV-16 E7 overlapping peptide pools using the IFN-γ ELISPOT assay.
  
  
  RESULTS
  The E7 sequence comprising amino acids 16-55 was a major immunogenic region. The CMI response to HPV-16 E7 is highly type-specific. The follow-up CMI response may last longer than expected after the lesion is resected.
  
  
  CONCLUSIONS
  We found that the E7 sequence comprising amino acids 16-55 is a major immunogenic region that is critical for the T-cell-mediated immune response with CIN2/3 or cervical cancer. The identification of CMI responses to HPV-16 E7 peptide pools may provide insight into therapeutic vaccine trials for the control of HPV-associated diseases.
authors.affiliation: Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
authors.forename: Yong Seok
authors.initials: YS
authors.lastname: Lee
authors.forename: Chung Won
authors.initials: CW
authors.lastname: Lee
authors.forename: Min Jong
authors.initials: MJ
authors.lastname: Song
authors.forename: Eun Mi
authors.initials: EM
authors.lastname: Ho
authors.forename: Chan Joo
authors.initials: CJ
authors.lastname: Kim
authors.forename: Tae Chul
authors.initials: TC
authors.lastname: Park
authors.forename: Tai Gyu
authors.initials: TG
authors.lastname: Kim
authors.forename: Jong Sup
authors.initials: JS
authors.lastname: Park
mesh_terms: D000328:Adult; D000957:Antigens, Viral, Tumor / Q000276:immunology*; D058501:Enzyme-Linked Immunospot Assay; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular; D008875:Middle Aged; D050725:Papillomavirus E7 Proteins / Q000737:chemistry / Q000276:immunology*; D030361:Papillomavirus Infections / Q000276:immunology*; D053918:Papillomavirus Vaccines; D011446:Prospective Studies; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
chemical_list: D000957:Antigens, Viral, Tumor; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; C059731:oncogene protein E7, Human papillomavirus type 16